Alkermes PLC reported data that suggest its drug for major depressive disorder in patients who don’t respond well to standard therapies will work. ALKS 5461 produced statistically significant improvement on three rating scales, compared to a placebo. A press release said ALKS 5461 reflects a new approach “based on modulation of opioid receptors in the brain and is designed as a non-addictive, oral, once-daily medicine.” Based in Ireland, Alkermes has a research center in Waltham.
Alkermes cites positive results
You've reached the limit of 10 free articles a month
Stay informed with unlimited access to Boston’s trusted news source.
- High-quality journalism from the region’s largest newsroom
- Convenient access across all of your devices
- Today’s Headlines daily newsletter
- Subscriber-only access to exclusive offers, events, contests, eBooks, and more
- Less than $1 a week